The call ran from 8:29 AM to 9:17 AM IST (48 min).
Key takeaways
Revenue rose 21% YoY to ₹2,370 Cr, but PAT was only ₹31 Cr as margins fell on Montreal losses (>₹80 Cr in Q2). Management guides H2 mid-teen margins and deferred FY28 guidance.
| Revenue growth | Q2 revenue +21% YoY to ₹2,370 Cr; H1 +19% to ₹4,599 Cr. |
|---|---|
| Margins | EBITDA margins fell YoY; H2 guided mid-teens, improving QoQ. |
| Order book | Line 4 book strongest ever; 23 active proposals; no order book figure disclosed. |
| Demand visibility | US isolator demand strong; Line 4 RFPs at record; 23 active proposals. |
| Management confidence | Balanced; confident H2 recovery, but FY28 guidance deferred. |
Growth
Q2 revenue +21% YoY, H1 +19%; broad-based, but EBITDA margins fell YoY on Montreal and SPECT shortfall.
Outlook
H2 average EBITDA margin mid-teens; FY27 capex ₹1,800–1,900 Cr, FY28 ~₹1,000 Cr; net debt ~₹4,000 Cr end-FY27.
Risks
Montreal losses (₹157 Cr H1 plus ~₹200 Cr earlier) and SPECT supply gaps; FY28 guidance deferred; API pricing pressure.
Last quarter's promises, checked
Delivered
- Guided FY27 growth 'low double digits' → H1 +19% (= BEAT)
Partly delivered
- Guided Line 3 FY27 revenue $60–80M → ~$20M in Q2 (= PARTIAL)
- Guided Ruby-Fill '30%+' growth → ~30% annualised Q2 (= PARTIAL)
Missed
- Guided H2 EBITDA margin 17–18% → now 'mid-teens' (= MISS)
- Guided Montreal FY27 loss ~FY26's ~₹200 Cr → H1 alone ₹157 Cr (= MISS)
- Guided capex ~₹1,668 Cr and net debt falling from FY28 → capex ₹1,800–1,900 Cr, net debt ~₹4,000 Cr end-FY27 (= MISS)
Summary by ALFA Finder, written with AI assistance from the earnings call transcript the company filed, published . Open it on ALFA Filings ›
The results behind this call
Jubilant Pharmova Q2 FY27 Results: Net Profit ₹31 Cr, Down 74.1% YoY
Jubilant Pharmova Ltd reported revenue from operations of ₹2,370 Cr (+20.5% YoY) and net profit of ₹31 Cr (-74.1% YoY) for Q2 FY27.
- Key figure
- Net profit ₹31 Cr · -74.1% YoY
What management said last time
Full summary →From the call summary published .
Outlook they gave
Guided H2FY27 EBITDA margins of 17-18%. Committed to net debt zero by 2030. Commencing commercial production on Line 3 late FY2027.
Growth they described
FY26 Revenue up 14% to ₹8,280 Cr; EBITDA up 8% to ₹1,326 Cr; Normalized PAT up 7% to ₹4,422 Cr.
Call details
| Company | Jubilant Pharmova Ltd |
|---|---|
| NSE symbol | JUBLPHARMA |
| ISIN | INE700A01033 |
| Call | Q2 FY27 earnings call |
| Date | Monday, 16 November 2026 |
| Time | 8:30 AM IST |
| Length | 48 min |
Jubilant Pharmova Ltd: key numbers
- Share price
- ₹935.05
- Market cap
- ₹14,894 Cr
- Revenue (annual)
- ₹8,280 Cr
- Net profit (annual)
- ₹398.5 Cr
- P/E (TTM)
- 56.6×Sector 49.0×
- Promoter holding
- 47.68%+0.00% QoQ
- FII holding
- 15.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.